Evidence map›Paper›PMID 40778124›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Real-time, multi-pathogen wastewater genomic surveillance with Freyja 2.

Joshua I Levy, Praneeth Gangavarapu, Dylan A Pilz, Maryam Ahmadi Jesvaghane, Allison Steedman, Mark Zeller, Karthik Gangavarapu, Daniel McDonald, Kevin Libuit, Curtis Kapsak and 10 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Joshua I LevyDepartment of Translational Medicine, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-7573-7793
Praneeth GangavarapuDepartment of Translational Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Dylan A PilzDepartment of Translational Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Maryam Ahmadi JesvaghaneDepartment of Translational Medicine, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0002-8970-2601
Allison SteedmanDepartment of Translational Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Mark ZellerDepartment of Translational Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Karthik GangavarapuDepartment of Translational Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Daniel McDonaldDepartment of Pediatrics, University of California San Diego, La Jolla, CA, USA.
Kevin LibuitTheiagen Genomics, Highlands Ranch, CO, USA.
Curtis KapsakTheiagen Genomics, Highlands Ranch, CO, USA.ORCID 0000-0002-8735-1190
Erin L YoungUtah Public Health Laboratory, Utah Department of Health and Human Services, State of Utah, Taylorsville, UT, USA.
Shelesh AgrawalDepartment of Water and Environmental Biotechnology, Institute IWAR, Technical University of Darmstadt; Darmstadt, 64287, Germany.
Laura OrschlerDepartment of Water and Environmental Biotechnology, Institute IWAR, Technical University of Darmstadt; Darmstadt, 64287, Germany.
Martin HölzerBioinformatics and Translational Research, Genome Competence Center, Robert Koch Institute; Berlin 13353, Germany.ORCID 0000-0001-7090-8717
Elyse StachlerThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Daniel J ParkThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Angie S HinrichsGenomics Institute, University of California, Santa Cruz, Santa Cruz, CA, USA.
Louise C LaurentExpedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.
Rob KnightDepartment of Pediatrics, University of California San Diego, La Jolla, CA, USA.
Kristian G AndersenDepartment of Translational Medicine, The Scripps Research Institute, La Jolla, CA, USA.

Funding

Viral Genomics: evolution, spread, and host interactionsU19AI110818 · NIAID · BROAD INSTITUTE, INC. · PI NEAFSEY, DANIEL E · 2014 to 2024
$66.5M
Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Robert F Garry · 2018 to 2026
$32.0M
Scripps Translational Science InstituteUL1TR002550 · NCATS · SCRIPPS RESEARCH INSTITUTE, THE · PI TOPOL, ERIC JEFFREY · 2018 to 2022
$28.9M
West African Emerging Infectious Disease Research Center (WA-EIDRC)U01AI151812 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ANDERSEN, KRISTIAN GRAUGAARD, GARRY, ROBERT F · 2020 to 2024
$13.2M
PATHOGENESIS AND IMMUNOLOGY OF DISEASET32AI007244 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI NEMAZEE, DAVID · 1985 to 2022
$8.8M
Mapping host-microbe-metabolite interactions in 3D to find diet-derived enhancers of immunityDP1AT010885 · NCCIH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KNIGHT, ROB · 2019 to 2023
$5.5M
NCATS NIH HHS UL1 TR002550NCCIH NIH HHS DP1 AT010885NIAID NIH HHS T32 AI007244NIAID NIH HHS U01 AI151812NIAID NIH HHS U19 AI110818NIAID NIH HHS U19 AI135995
6 · The paper itself

Abstract

Case-based infectious disease surveillance is fundamental to public health, but is resource-intensive, logistically complex, and prone to sampling bias. Wastewater testing and sequencing have increasingly been used for population-scale monitoring of pathogen dynamics, including in low-resource settings. Broader adoption of wastewater genomic surveillance, however, is limited by a lack of flexibility across sequencing platforms and approaches, and adaptability to additional pathogens. Here, we describe "Freyja 2", an integrated bioinformatics tool enabling robust real-time inference of pathogen lineage prevalence and growth dynamics from wastewater and other complex samples. In Freyja 2, we develop new methods for estimating lineage prevalence and growth rates, and demonstrate robustness across common sequencing platforms and to low genomic coverage. By incorporating global pathogen data streams, we extend Freyja 2 to support multi-pathogen surveillance. We demonstrate tracking of multiple recent or ongoing public health emergencies, including COVID-19, mpox, and H5N1 influenza, revealing unreported diversity and lineage co-circulation.

Identifiers

PMID40778124
PMCPMC12330420

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.